ScaleReady announces a G-Rex® Grant has been awarded to Verismo Therapeutics
Summary
ST. PAUL, Minn., Sept. 17, 2024 /PRNewswire/ -- ScaleReadyTM, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH), and CellReadyTM, today announced that it has awarded a $150,000 G-Rex Grant to Verismo Therapeutics, a clinical-stage CAR T company developing the novel KIR-CAR platform technology. "This funding will help us further optimize our cell therapy manufacturing processes by transitioning our active and future pipeline to G-Rex\xae, ensuring we can deliver life-saving treatments to patients more efficiently and cost-effectively. The G-Rex Grant will play a pivotal role in advancing the companys research and development efforts, ultimately contributing to the broader goal of making innovative treatments accessible to those in need.About the KIR-CAR Platform The KIR-CAR platform is a multi-chain CAR T cell therapy and has been shown in preclinical animal models to be capable of maintaining antitumor T cell activity even in challenging tumor microenvironments. Verismo is the only company developing the KIR-CAR platform, using a modified NK cell derived receptor and DAP12 pairing, designed to improve persistence and efficacy against aggressive tumors. The KIR-CAR platform technology was developed specifically to address areas of high unmet medical need, including advanced solid tumors and B cell associated disorders and malignancies.